Programmed death-ligand 1 expression in tumor cells and tumor-infiltrating lymphocytes are associated with depth of tumor invasion in penile cancer

被引:2
|
作者
Sangkhamanon, Sakkarn [1 ]
Kotano, Natcha [1 ]
Sirithanaphol, Wichien [2 ]
Rompsaithong, Ukrit [2 ]
Kiatsopit, Pakorn [2 ]
Sookprasert, Aumkhae [3 ]
Wirasorn, Kosin [3 ]
Twinprai, Prin [4 ]
Watcharenwong, Piyakarn [3 ]
Chindaprasirt, Jarin [3 ,5 ]
机构
[1] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen 40002, Thailand
[2] Khon Kaen Univ, Fac Med, Dept Surg, Div Urol Surg, Khon Kaen 40002, Thailand
[3] Khon Kaen Univ, Fac Med, Dept Internal Med, Div Med Oncol, Khon Kaen 40002, Thailand
[4] Khon Kaen Univ, Fac Med, Dept Radiol, Khon Kaen 40002, Thailand
[5] Khon Kaen Univ, Fac Med, Dept Internal Med, Div Med Oncol, 123 Mitraparp Rd, Khon Kaen 40002, Thailand
关键词
penile cancer; PD-L1; programmed death-ligand 1; squamous cell carcinoma of penis; PD-L1; EXPRESSION;
D O I
10.3892/br.2023.1627
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The present study aimed to demonstrate the proportion of the programmed death-ligand 1 (PD-L1) expression in penile cancer patients and the association with clinicopathological parameters. Formalin-fixed paraffin-embedded specimens were obtained from 43 patients with primary penile squamous cell carcinoma treated at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, between 2008 and 2018. PD-L1 expression was evaluated by the immunohistochemistry using an SP263 monoclonal antibody. PD-L1 positivity was defined as >25% tumor cell staining or >25% tumor-associated immune cell staining. The correlation between PD-L1 expression and clinicopathological parameters was analyzed. A total of eight of 43 patients (18.6%) were identified as positive for PD-L1 expression in tumor cells and tumor-infiltrating lymphocytes. In the PD-L1 positive group, there was a significant association with pathological T stage (P=0.014) with a higher percentage of PD-L1 positive tumors in T1 stage compared with T2-T4 stage. In this cohort, there was a trend towards longer survival in patients with positive PD-L1 expression (5-year OS: 75% vs. 61.2%, P=0.19). Lymph node involvement and the location of tumor at the shaft of penis were two independent prognostic factors for survival. In conclusion, the PD-L1 expression was detected in 18% of penile cancer patients and high expression of PD-L1 was associated with the early T stage.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression
    Chen, Man-Chin
    Pangilinan, Christian Ronquillo
    Lee, Che-Hsin
    CANCERS, 2020, 12 (01)
  • [42] Tumor-infiltrating lymphocytes in human gastric cancer and disseminated tumor cells
    Osinsky, S.
    Kovelskaya, A.
    Bubnovskaya, L.
    Osinsky, D.
    Ganusevich, I.
    Gumenyuk, L.
    Merentsev, S.
    Mamontova, L.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S165 - S165
  • [43] Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer
    Deacu, Mariana
    Tuta, Liliana-Ana
    Bosoteanu, Madalina
    Aschie, Mariana
    Mitroi, Anca Florentina
    Nicolau, Antonela-Anca
    Enciu, Manuela
    Cojocaru, Oana
    Petcu, Lucian Cristian
    Baltatescu, Gabriela Izabela
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2021, 62 (01): : 63 - 71
  • [44] Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma
    Gross, Daniel J.
    Chintala, Navin K.
    Vaghjiani, Raj G.
    Grosser, Rachel
    Tan, Kay See
    Li, Xiaoyu
    Choe, Jennie
    Li, Yan
    Aly, Rania G.
    Emoto, Katsura
    Zheng, Hua
    Dux, Joseph
    Cheema, Waseem
    Bott, Matthew J.
    Travis, William D.
    Isbell, James M.
    Li, Bob T.
    Jones, David R.
    Adusumilli, Prasad S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 89 - 102
  • [45] Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma
    Losi, Lorena
    Bertolini, Federica
    Guaitoli, Giorgia
    Fabbiani, Luca
    Banchelli, Federico
    Ambrosini-Spaltro, Andrea
    Botticelli, Laura
    Scurani, Letizia
    Baldessari, Cinzia
    Barbieri, Fausto
    Cascinu, Stefano
    Maiorana, Antonin
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 55 (05) : 1157 - 1164
  • [46] Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma
    Shima, Toshiyuki
    Shimoda, Masayuki
    Shigenobu, Takao
    Ohtsuka, Takashi
    Nishimura, Tomoyasu
    Emoto, Katsura
    Hayashi, Yuichiro
    Iwasaki, Tatsuro
    Abe, Takayuki
    Asamura, Hisao
    Kanai, Yae
    CANCER SCIENCE, 2020, 111 (02) : 727 - 738
  • [47] PROGRAMMED DEATH LIGAND-1 (PD-L1) EXPRESSION STATUS IN PENILE SQUAMOUS CELL CARCINOMA TUMOR CELLS AND TUMOR INFILTRATING IMMUNE CELLS
    Rider, Jennifer
    Harlow, Alyssa
    Giunchi, Francesca
    Carlsson, Jessica
    Kirrander, Peter
    Fiorentino, Michelangelo
    Andren, Ove
    Davidsson, Sabina
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1129 - E1130
  • [48] The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene
    Li, Yanchun
    Opyrchal, Mateusz
    Yao, Song
    Peng, Xuan
    Yan, Li
    Jabbour, Hossam
    Khoury, Thaer
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 293 - 302
  • [49] The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene
    Yanchun Li
    Mateusz Opyrchal
    Song Yao
    Xuan Peng
    Li Yan
    Hossam Jabbour
    Thaer Khoury
    Breast Cancer Research and Treatment, 2018, 170 : 293 - 302
  • [50] Clinical relevance and significance of programmed death-ligand I expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma
    Quan, Huatao
    Yan, Li
    Wang, Shuyi
    Wang, Shengzi
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4335 - 4345